Technical analysis of Pulmonx Corporation (LUNG): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Pulmonx Corporation is a biomedical technology firm dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases. Its primary offering, the Zephyr Endobronchial Valve, is specifically engineered to treat bronchoscopic hyperinflation in adults afflicted with severe emphysema. Complementing its therapeutic solutions, the company also provides the Chartis Pulmonary Assessment System.
Price Performance
| 1 month | -13.91% |
| 3 months | +54.69% |
| Year-to-date | -10.41% |
| 1 year | +17.16% |
| 3 years | -81.23% |
| 5 years | -94.69% |
52-Week Range
| 52-week High | $2.89 |
| 52-week Low | $1.13 |
| Avg Volume (90d) | 517K |
Technical Indicators
| SMA 50 | $1.91 |
| SMA 200 | $1.69 |
| Beta | 0.19 |
| 30-day Volatility (annualised) | 75.9% |
| Price vs SMA 50 | +3.7% |
| Price vs SMA 200 | +16.8% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $2.00 | |
| 2025-11 | $1.62 | -19.0% |
| 2025-12 | $2.21 | +36.4% |
| 2026-01 | $1.64 | -25.8% |
| 2026-02 | $1.58 | -3.7% |
| 2026-03 | $1.29 | -18.4% |
| 2026-04 | $1.28 | -0.8% |
| 2026-05 | $1.65 | +28.9% |
| 2026-06 | $1.30 | -21.2% |
| 2026-07 | $1.63 | +25.4% |
| 2026-08 | $2.38 | +46.0% |
| 2026-09 | $1.98 | -16.8% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-16 | $1.28 | $8.32B |
| 2026-09-16 | | $9M |
| 2026-09-16 | | |
| 2026-09-16 | $-3.22 | $9M |
| 2026-09-16 | $-0.07 | $51M |
| 2026-09-16 | $-1.99 | $12M |
Price
| Price | $2.07 |
| Market Cap | $87M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 2.28 |
| EV / EBITDA | -2.18 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 1.43 |
| Current Ratio | 4.32 |